(3.80.6.131) 您好!臺灣時間:2021/05/14 02:28
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:黃沛芸
研究生(外文):Pei-Yun
論文名稱:Camphortaimide B 抗癌活性及其作用機制之研究
論文名稱(外文):Studies of the anticancer effect and molecular mechanisms of camphortaimide B
指導教授:曾翠華曾翠華引用關係
指導教授(外文):Tsui-Hwa Tseng
學位類別:碩士
校院名稱:中山醫學大學
系所名稱:生化暨生物科技研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2010
畢業學年度:98
語文別:中文
論文頁數:79
相關次數:
  • 被引用被引用:1
  • 點閱點閱:389
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
牛樟芝(Antrodia camphorata)屬多孔菌科,只生長於台灣特有牛樟樹,生長緩慢且數量稀少。傳統上樟芝子實體用來治療腹瀉、腹痛、高血壓與肝癌,樟芝子實體與菌絲體萃取物的生物功能過去已被廣泛的研究,包括抗氧化、抗發炎、抗癌,然而有關樟芝成分結構及其生物活性則鮮少被研究。本研究以合成的樟芝菌絲體中馬來酸衍生物camphorataimide B來進行實驗,探討其對乳癌細胞MDA-MB-231的侵犯、轉移作用的影響。首先我們研究camphorataimide B是否可以抑制乳癌細胞增生,以細胞毒性分析(MTT)、細胞聚落形成(colony formation assay),發現camphorataimide B能有效抑制乳癌細胞增長,接著以DAPI染色和DNA斷裂進行分析,結果發現大於10 μM的camphorataimide B會造成乳癌細胞的細胞凋亡現象;也發現camphorataimide B可以誘導MDA-MB-231細胞造成細胞週期停止於G2/M期。再來我們以細胞發散性測定、F-actin 的螢光染色、傷口癒合、Boyden chamber 移動等試驗看到camphorataimide B會抑制乳癌細胞的移動能力。更進一步我們想要了解camphorataimide B會不會也抑制了乳癌細胞的侵犯能力,所以我們先進行貼附能力試驗,再以Boyden chamber 模擬細胞基質進行侵犯試驗,結果顯示camphorataimide B也抑制了乳癌細胞的侵犯作用。再來利用西方墨點法、zymography 的分析方式分析細胞侵犯相關蛋白及蛋白酶的表現,最後發現camphorataimide B是抑制了組蛋白酶(cathepsin D)的表現,同時我們也發現了調控cathepsin D的轉錄因子缺氧誘導因子(hypoxia-inducible factor-1α, HIF-1α)也受到了camphorataimide B的抑制。同時我們利用動物實驗模式研究camphorataimide B對乳癌細胞在裸鼠中肺部移生的影響,結果發現camphorataimide B減少肺部大小、重量和肺部移生現象。

Abstract
Antrodia camphorata, known as“niu-chang-chin”in Taiwan, is a fungus of the family polyporaceae that grows slowly and rare species. Traditionally, the fruit body of Antrodia camphorata used to treat diarrhea, abdominal pain, hypertension, and liver cancer. Many previous studies reported that the extract of fruit body and mycelium of Antrodia camphorata possesses a wide range of biological functions, such as antioxibant, anti-inflammation, anticancer. However, the relationship of structure bioactive component of Antrodia camphorata and bioactivity is not well known. In this studies, we investigated the anticancer potential of synthetic camphora-
taimide B, the maleic derivatives from the mycelium, on MDA-MB-231 breast cancer cells. First, we studied whether camphorataimide B can inhibit breast cancer cells growth by cytotoxicity assay and colony formation assay. The results showed that camphorataimide B can restrain the proliferation of breast cancer cells. In addition, by
DAPI staining and DNA fragmentation assay, the results found camphorataimide B induced apoptosis of MDA-MB-231 B breast cancer cells at concentrations of 10-40 μM. Furthermore, camphorataimide B was able to induce cell cycle arrest in G2/M phase. Then, we performed cell scattering, F-actin fluoresence staining, wound healing, and Boyden chamber migration assay to examine anti-migration of camphora
-taimide B on breast cancer cells. Moreover, we want to know whether camphorataimi
-de B will also inhibit breast cancer cell invasion. We conducted adhesion assay and Boyden chamber invasion assay. We found that camphorataimide B also inhibited breast cancer cells invasion. By weatern blotting analysis, it showed camphora
-taimide B suppressed the expression of cathepsin D and HIF-1α, a transcription factor of cathepsin D. Finally, we used animal models to study camphorataimide B on lung colonization of MDA-MB-231 cells in nude mice. The results showed camphora-
taimide B reduced the size and weigth of lung as well as lung colonization of MDA-MB-231 cells.


目 錄

縮寫表 .................................................... II
中文摘要 ....................................................... 01
英文摘要 ....................................................... 02
壹、 緒論 ...................................................... 04
第一部分 癌症(Cancer) ..................................... 04
第二部分 藥物來源 .......................................... 06
第三部分 癌症轉移(metastasis)............................... 08
貳、 研究背景與動機 ............................................ 14
參、 實驗材料與實驗方法 ........................................ 15
肆、 實驗結果 .................................................. 30
伍、 討論 ...................................................... 40
陸、 參考文獻 .................................................. 43
柒、 實驗結果圖表 .............................................. 48
捌、 附圖 ...................................................... 76


Ao, Z. H., Xu, Z.H., Lu, Z.M., Xu, H.Y., Zhang, X.M., Dou, W.F. (2009). "Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases." J Ethnopharmacol, 121(2): 194-212.

Aqueveque, P., Anke, T., Sterner, O. (2002). "The himanimides, new bioactive compounds from Serpula himantoides (Fr.) Karst." Z. Naturforsch, 57(3-4): 257-262.

Benes, P., Vetvicka, V., Fusek, M. (2008). "Cathepsin D—Many functions of one aspartic protease." Crit Rev Oncol Hematol, 68(1): 12-28.

Chabottaux, V., Noel, A. (2007). "Breast cancer progression: insights into multifaceted matrix metalloproteinases. ." Clin Exp Metastasis, 24(8): 647-656.

Chan-Hui, P. Y., Weaver, R. (1998). "Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades." Biochem J, 15(336): 599-609.

Chang, C.F., Lai, Z.C.; Lee, Y.J. (2008) "Total synthesis of (±)-camphorataimides and
(±)-himanimides by NaBH4/Ni(OAc)2 or Zn/AcOH stereoselective reduction.",
Tetrahedron, 64: 4347-4353

Cunat, S., Hoffmann, P., Pujol, P. (2004). "Estrogens and epithelial ovarian cancer." Gynecol Oncol, 94: 25-32.

Deryugina, E. I., Quigley, J.P. (2006). "Matrix metalloproteinases and tumor metastasis." Cancer Metastasis Rev, 25(1): 9-34

Evan, G. I., Vousden, K.H. (2001). "Proliferation, cell cycle and apoptosis in cancer." Nature, 411(6835): 342-348.

Fidler, I. J. (2002). "The organ microenvironment and cancer metastasis." Differentiation, 70(9-10): 498-505.

Fidler, I. J. (2003). "The pathogenesis of cancer metastasis: the ''seed and soil'' hypothesis revisited." Nat Rev Cancer, 3 (6): 453-458.

Fiebig, H. H., Maier, A., Burger, A.M. (2004). "Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery." Eur J Cancer, 40(6): 802-820.

Grube, G., Greiner, R.H., Hlushchuk, R., Aebersold, D.M., Altermatt, H.J., Berclaz,
G., Djonov, V.(2004). "Hypoxia-inducible factor 1 alpha in high-risk breast cancer:
an independent prognostic parameter?" Breast Cancer Res, 6(3): R191-198.

Hanahan, D., Weinberg, R.A. (2000). "The Hallmarks of Cancer." Cell, 100(1): 57-70.

Harbeck, N. (2008). "Never too late:reducing late brease cancer relapse risk." Curr Med Res Opin, 24(12): 3295-3305.

Herschman, H. R. (1996). "Prostaglandin synthase 2." Biochim Biophys Acta, 1299(1): 125-140.

Hood, J. D., Cheresh, D.A. (2002). "Role of integrins in cell invasion and migration." Nat Rev Cance, 2(2): 91-100.

Howe, L. R. (2007). "Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer." Breast Cancer Research, 9(210): 1-9.

Karin, M. (1998). "Mitogen-activated protein kinase cascades as regulators of stress responses." Ann N Y Acad Sci, 851: 139-146.

Kessenbrock, K., Plaks, V., Werb, Z. (2010). "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment." Cell, 141(1): 52-67.

Kornfeld, S. (1990). "Lysosome enzyme targeting." Biochem Soc Trans, 18(3): 367-374.

Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., Semenza, G.L. (2003). "Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor 1." Cancer Res, 63(5): 1138-1143.

Lewis, T. S., Shapiro, P.S., Ahn, N.G. (1998). "Signal transduction through MAP kinase cascades." Adv Cancer Res, 74: 49-139.

Li, J. M., Brooks, G. (1999). "Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?" Eur Heart J, 20(6): 406-420.

Luo, Y., He, D.L., Ning. L., Shen, S.L., Li, L., Li, X., Zhau, H.E., Chung, L.W.
(2006). "Over-expression of hypoxia-inducible factor-1alpha increases the invasive
potency of LNCaP cells in vitro." BJU Int, 98(6): 1315-1319.

McGill, C. J., Brooks, G. (1995). "Cell cycle control mechanisms and their role in cardiac growth." Cardiovasc Res, 30(4): 557-569.

Nagase, H., Woessner, J.F. (1999). "Matrix Metalloproteinases." J Biol Chem, 274(31): 21491-21494.

Nakamura, N., Hirakawa, A., Gao, J.J., Kakuda, H., Shiro, M., Komatsu, Y., Sheu, C.C., Hattori, M. (2004). "Five New Maleic and Succinic Acid Derivatives from the Mycelium of Antrodia camphorata and Their Cytotoxic Effects on LLC Tumor Cell Line." J Nat Prod, 67(1): 46-48.

Nomura, T., Katunuma, N. (2005). "Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells." J Med Invest, 52(1-2): 1-9.

Ohri, S. S., Vashishta, A., Proctor, M., Fusek, M., Vetvicka, V. (2008). "The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells." Int J Oncol, 32(2): 491-498.

Page-McCaw, A., Ewald, A.J., Werb, Z. (2007). "Matrix metalloproteinases and the regulation of tissue remodelling." Nat Rev Mol Cell Biol, 8(3): 221-233.

Rofstad, E. K. (2000). "Microenvironment-induced cancer metastasis." Int J Radiat Biol, 76(5): 589-605.

Sellès, P. (2005). "Synthesis and Biological Evaluation of Himanimide C and Unnatural Analogues." ORGANIC LETTERS, 7(4): 605-608.

Semenza, G. L. (2003). "Targeting HIF-1 for cancer therapy." Nat Rev Cancer, 3(10): 721-732.

Shah, M. A., Schwartz, G.K. (2001). "Cell cycle-mediated drug resistance: an emerging concept in cancer therapy." Clin Cancer Res, 7(8): 2182-2194.

Shen, C. C., Yang, H.C., Huang, R. L., Chen J.C., Chen, C.C. (2005). "Anti-HBV principlefrom the culture broth of Antrodia camphorata." J Chin Med, 16(1): 57-61.

Smith, H. W., Marshall, C.J. (2010). "Regulation of cell signalling by uPAR." Nat Rev Mol Cell Bio,. 11(1): 23-36.

Steeg, P. S. (2003). "Metastasis suppressors alter the signal transduction of cancer cells." Nat Rev Cancer, 3(1): 55-63.

Sennoune, S.R., Bakunts, K., Martinez, G.M., Chua-Tuan, J.L., Kebir, Y., Attaya,
M.N., Maetinez-Zaquilan, R. (2004). "Vacuolar H+-ATPase in human breast cancer
cells with distinct metastatic potential: distribution and functional activity." Am J
Physiol Cell Physiol, 286(4): C1443-1452.

Stricker, J., Falzone, T., Gardel, M.L. (2010). "Mechanics of the F-actin cytoskeleton." J Biomech, 43(1): 9-14.

Subbaramaiah, K., Dannenberg, A.J. (2003). "Cyclooxygenase 2: a molecular target for cancer prevention and treatment " Trends Pharmacol Sci, 24(2): 96-102.

Subbaramaiah, K., Zakim, D., Weksler, B.B., Dannenberg, A.J. (1997). "Inhibition of cyclooxygenase: a novel approach to cancer prevention." Proc Soc Exp Biol Med, 216(2): 201-210.

Thorpe, S. M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I.J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B.B., Rose, C. (1989). "Association between High Concentrations of Mr 52,000 Cathepsin D and Poor Prognosis in Primary Human Breast Cancer." Cancer Res, 49(21): 6008-6014.

Wang, D., Dubois, R.N. (2006). "Prostaglandins and cancer." Gut, 55(1): 115-122.

Yang, S. W., Shen, Y.C., Chen, C.H. (1996). "Steroids and triterpenoids of Antrodia cinnamomea – A fungus parasitic on Cinnamomum micranthum." Phytochemistry, 41(5): 1389-1392.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 35. 翁慧卿(2005)。醫療服務消費者醫院選擇之集群分析-以婦產科生產醫療服務為例。福爾摩莎醫務管理雜誌,1卷2期,145-155頁。
2. 30. 邱文達(2004)。建構以病人為中心的醫療品質服務。品質月刊,40卷9期。
3. 28. 林素吟、丁學勤(2004)。產品屬性、程序屬性與顧客滿意度的關係模式。管理評論,23卷2期,29-43頁。
4. 27. 林美珠、李玉春(2003)。全民健保中醫門診總額支付制度實施前醫療服務品質之研究。臺灣公共衛生雜誌,22卷3期,204-216頁。
5. 24. 林松茂(2007)。麥可波特大師演講醫療品質文章讀後感:談以重視醫療照護的價值來啟動醫療改革與創造高價值的醫療照護。品質月刊,43卷8期,14-18頁。
6. 22. 周文賢、楊明璧、賴曉慧(2005)。品牌形象契合度及產品屬性契合度對消費者購買延伸產品意願之研究。交大管理學報,25卷1期,97-122頁。
7. 16. 呂惠富(2008)。促銷活動對於運動鞋品牌評價及購買意願之影響。休閒暨觀光產業研究,3卷1期,1-14頁。
8. 12. 吳肖琪、吳義勇、朱慧凡、林嘉彥、李鐘祥、張錦文、藍忠孚(2002)。我國醫院醫療品質指標使用之情形。醫療品質,2卷2期,1-14頁。
9. 8. 石曜堂、張政國(2008)。醫療品質發展趨勢探討。臺灣醫學,12卷6期,685-690頁。
10. 7. 石曜堂(1978)。醫療品質評估。醫院雜誌,11卷2期,106-109頁。
11. 4. 王健全(2008)。台灣醫療服務産業的國際化及其展望。經濟前瞻,117期,100-104頁。
12. 3. 王庭荃、楊長興(2008)。醫師年資、醫療服務量與消化性潰瘍治療效果之相關研究。臺灣公共衛生雜誌,27卷1期,57-66頁。
13. 36. 耿慶瑞、劉凱銘、黃增隆(2006)。互動廣告對經驗產品屬性轉換之研究。電子商務學報,8卷1期,101-128頁。
14. 38. 張景盛、翁慧卿、徐村和(2007)。從服務接觸觀點探討不同科別醫療服務品質之差異-以一般科與婦產科門診為例。品質學報,14卷3期,301-315頁。
15. 39. 陳仁惠、鄭仲興、方世杰(2005)。門診醫療服務品質與病患滿意度對於關係導向行為之影響。醫護科技學刊,7卷2期,187-202頁。
 
系統版面圖檔 系統版面圖檔